F
Z. I. Günler et al.
Paper
Synthesis
1H NMR (400 MHz, CDCl3): δ = 7.18 (d, J = 8.6 Hz, 2 H), 6.82 (d, J = 8.6
Hz, 2 H), 4.70–4.50 (m, 2 H), 3.90 (m, 1 H), 3.75 (s, 3 H), 2.89 (m, 2 H),
2.08 (s, 3 H).
(R)-5-Nitro-4-(4-(trifluoromethyl)phenyl)pentan-2-one (2h)22
The preparative Michael addition procedure was followed using
trans-4-trifluoromethyl-β-nitrostyrene (217 mg, 1 mmol). Product
2h (149 mg, 0.54 mmol, 54% isolated yield; 84% ee (R)) was obtained
as a white solid.
(R)-4-(2-Methoxyphenyl)-5-nitropentan-2-one (2c)20
The preparative Michael addition procedure was followed using
trans-2-methoxy-β-nitrostyrene (179 mg, 1 mmol). Product 2c (190
mg, 0.80 mmol, 80% isolated yield; 91% ee (R)) was obtained as a
white solid.
HPLC (Phenomenex Lux 5 μm Amylose-2 column, hexane–i-PrOH,
90:10, 1 mL/min, 209 nm): tR = 13.7 (major), 14.9 (minor) min.
1H NMR (400 MHz, CDCl3): δ = 7.23 (m, 2 H), 7.01 (m, 2 H), 4.75–4.50
(m, 2 H), 4.01 (m, 1 H), 2.82 (m, 2 H), 2.10 (s, 3 H).
HPLC (Phenomenex Lux 5 μm Amylose-2 column, hexane–i-PrOH,
90:10, 1 mL/min, 209 nm): tR = 21.0 (major), 23.2 (minor) min.
1H NMR (400 MHz, CDCl3): δ = 7.25–6.83 (m, 4 H), 4.70 (m, 2 H), 4.22
(m, 1 H), 3.80 (s, 3 H), 3.00 (m, 2 H), 2.08 (s, 3 H).
Acknowledgment
Financial support from MINECO (Grants CTQ2015-70117-R and
CTQ2015-69136-R), Generalitat de Catalunya (Grants 2014SGR231
and 2014SGR827) and the ICIQ Foundation is acknowledged. We also
thank MINECO for a Severo Ochoa Excellence Accreditation 2014–
2018 (SEV-2013-0319). C.J. thanks the Ramón y Cajal program (RYC-
2010-06750) for financial support. Z.I.G. holds a FI-DGR predoctoral
fellowship (2013FI_B 00395).
(R)-4-(4-Bromophenyl)-5-nitropentan-2-one (2d)20
The preparative Michael addition procedure was followed using
trans-4-bromo-β-nitrostyrene (228 mg, 1 mmol). Product 2d (232
mg, 0.81 mmol, 81% isolated yield; 89% ee (R)) was obtained as a
white solid.
HPLC (Phenomenex Lux 5 μm Amylose-2 column, hexane–i-PrOH,
90:10, 1 mL/min, 209 nm): tR = 26.8 (major), 31.1 (minor) min.
1H NMR (400 MHz, CDCl3): δ = 7.48 (d, J = 8.4 Hz, 2 H), 7.12 (d, J = 8.4
Supporting Information
Hz, 2 H), 4.70–4.50 (m, 2 H), 4.02 (m, 1 H), 2.88 (m, 2 H), 2.14 (s, 3 H).
Supporting information for this article is available online at
S
u
p
p
o
nrtIo
g
f
rmoaitn
S
u
p
p
ortiInfogrmoaitn
(R)-5-Nitro-4-(p-tolyl)pentan-2-one (2e)21
The preparative Michael addition procedure was followed using
trans-4-methyl-β-nitrostyrene (163 mg, 1 mmol). Product 2e (122
mg, 0.55 mmol, 55% isolated yield; 87% ee (R)) was obtained as a
white solid.
References
(1) (a) Tsogoeva, S. B.; Wei, S. W. Chem. Commun. 2006, 1451.
(b) Yalalov, D. A.; Tsogoeva, S. B.; Schmatz, S. Adv. Synth. Catal.
2006, 348, 826.
(2) (a) Huang, H.; Jacobsen, E. N. J. Am. Chem. Soc. 2006, 128, 7170.
(b) Lalonde, M. P.; Chen, Y.; Jacobsen, E. N. Angew. Chem. Int. Ed.
2006, 45, 6366.
HPLC (Phenomenex Lux 5 μm Amylose-2 column, hexane–i-PrOH,
90:10, 1 mL/min, 209 nm): tR = 18.5 (major), 20.7 (minor) min.
1H NMR (400 MHz, CDCl3): δ = 7.30–6.80 (m, 4 H), 4.70 (m, 2 H), 4.21
(m, 1 H), 3.82 (s, 3 H), 3.05–2.85 (m, 2 H), 2.10 (s, 3 H).
(3) For reviews, see: (a) Serdyuk, O. V.; Heckel, C. M.; Tsogoeva, S. B.
Org. Biomol. Chem. 2013, 11, 7051. (b) Tsakos, M.; Kokotos, C. G.
Tetrahedron 2013, 69, 10199. (c) Peng, F.; Shao, Z. J. Mol. Catal.
A: Chem. 2008, 285, 1.
(R)-4-(2,4-Dichlorophenyl)-5-nitropentan-2-one (2f)22
The preparative Michael addition procedure was followed using
trans-2,4-dichloro-β-nitrostyrene (218 mg, 1 mmol). Product 2f (213
mg, 0.77 mmol, 77% isolated yield; 92% ee (R)) was obtained as a
white solid.
(4) For selected examples, see: (a) Tsakos, M.; Kokotos, C. G.;
Kokotos, G. Adv. Synth. Catal. 2012, 354, 740. (b) Kokotos, C. G.;
Kokotos, G. Adv. Synth. Catal. 2009, 351, 1355. (c) Dudzinski, K.;
Pakulska, A. M.; Kwiatkowski, P. Org. Lett. 2012, 14, 4222.
(5) (a) John, R. A. Biochim. Biophys. Acta 1995, 1248, 81.
(b) Maegley, K. A.; Admiraal, S. J.; Herschlag, D. Proc. Natl. Acad.
Sci. U.S.A. 1996, 93, 8160. (c) Jornvall, H.; Persson, B.; Krook, M.;
Atrian, S.; Gonzalez-Duarte, R.; Jeffery, J.; Ghosh, D. Biochemis-
try 1995, 34, 6003. (d) Shuman, S.; Schwer, B. Mol. Microbiol.
1995, 17, 405. (e) Radominska-Pandya, A.; Czernik, P. J.; Little, J.
M.; Battaglia, E.; Mackenzie, P. I. Drug Metab. Rev. 1999, 31, 817.
(f) Gefflaut, T.; Blonski, C.; Perie, J.; Willson, M. Prog. Biophys.
Mol. Biol. 1995, 63, 301.
HPLC (Phenomenex Lux 5 μm Amylose-2 column, hexane–i-PrOH,
90:10, 1 mL/min, 209 nm): tR = 23.8 (major), 28.5 (minor) min.
1H NMR (400 MHz, CDCl3): δ = 7.45–7.10 (m, 3 H), 4.75 (m, 2 H), 4.41
(m, 1 H), 3.10–2.80 (m, 2 H), 2.16 (s, 3 H).
(R)-4-(4-Fluorophenyl)-5-nitropentan-2-one (2g)20
The preparative Michael addition procedure was followed using
trans-4-fluoro-β-nitrostyrene (167 mg, 1 mmol). Product 2g (180 mg,
0.80 mmol, 80% isolated yield; 92% ee (R)) was obtained as a white
solid.
(6) Günler, Z. I.; Companyó, X.; Alfonso, I.; Burés, J.; Jimeno, C.;
Pericàs, M. A. Chem. Commun. 2016, 52, 6821.
HPLC (Phenomenex Lux 5 μm Amylose-2 column, hexane–i-PrOH,
90:10, 1 mL/min, 209 nm): tR = 15.8 (major), 17.2 (minor) min.
(7) For recent examples, see: (a) Serra-Pont, A.; Alfonso, I.; Jimeno,
C.; Solà, J. Chem. Commun. 2015, 51, 17386. (b) Kasaplar, P.;
Ozkal, E.; Rodríguez-Escrich, C.; Pericàs, M. A. Green Chem.
2015, 17, 3122. (c) Sagamanova, I. K.; Sayalero, S.; Martínez-
Arranz, S.; Albéniz, A. C.; Pericàs, M. A. Catal. Sci. Technol. 2015,
5, 754. (d) Jimeno, C.; Cao, L.; Renaud, P. J. Org. Chem. 2016, 81,
1251.
1H NMR (400 MHz, CDCl3): δ = 7.22 (m, 2 H), 7.02 (m, 2 H), 4.75–4.50
(m, 2 H), 4.01 (m, 1 H), 2.83 (m, 2 H), 2.12 (s, 3 H).
© Georg Thieme Verlag Stuttgart · New York — Synthesis 2016, 48, A–G